Micro- and Nanotechnologies for Intracellular Delivery by Yan, Li et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Micro- and Nanotechnologies for Intracellular Delivery
Citation for published version:
Yan, L, Zhang, J, Lee, C-S & Chen, X 2014, 'Micro- and Nanotechnologies for Intracellular Delivery' Small,
vol. 10, no. 22, pp. 4487-4504.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Small
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
  
1 
 
DOI: 10.1002/((please add manuscript number))  1 
Review 2 
 3 
Micro- and nanotechnologies for intracellular delivery 4 
Li Yan,† Jinfeng Zhang,† Chun-Sing Lee and Xianfeng Chen*  5 
 6 
Prof. Xianfeng Chen, Li Yan, Jinfeng Zhang, Prof. Chun-Sing Lee 7 
Center of Super-Diamond and Advanced Films (COSDAF) and Department of Physics and 8 
Materials Science, 9 
City University of Hong Kong, 10 
Hong Kong SAR, 11 
People’s Republic of China 12 
E-mail: xianfeng_chen@hotmail.com 13 
 14 
Keywords: intracellular delivery;targeted delivery;cell receptors;nanoneedle arrays 15 
 16 
†These authors contributed equally to this work. 17 
 18 
Abstract 19 
Majorities of drugs and biomolecules need to be delivered into cells to be effective. However, 20 
the cell membranes, a biological barrier, strictly resist drugs or biomolecules entering cells, 21 
resulting significantly reduced intracellular delivery efficiency. To overcome the cell 22 
membranes, a variety of intracellular delivery approaches including chemical and physical ways 23 
has been developed in recent years. In this review, we will focus on summarizing the 24 
nanomaterial routes involving in making use of a collection of receptors for targeted delivery 25 
of drugs and biomolecules and the physical ways of applying micro- and nanotechnologies for 26 
high-throughput intracellular delivery. 27 
 28 
1. Introduction 29 
Majorities of therapeutic targets are located within cell cytoplasm or nucleus. Thus drugs are 30 
only effective when they enter cells. However, the cell membranes, one of the most common 31 
biological barriers serving to isolate, protect and regulate cell from external environment, 32 
strongly limit the transport of drug molecules into the cytoplasm and nucleus and result in poor 33 
therapeutic efficacy. To overcome the barrier of the cell membranes and increase intracellular 34 
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delivery efficiency, many chemical and physical approaches involving micro- and 35 
nanotechnologies have been developed in the last decades. Chemical approaches are focused 36 
on applying nanostructured materials, made from polymers, lipids, peptides, inorganic and 37 
metallic substances, for intracellular delivery of a wide range of drugs, genes or other 38 
biomolecules.[1-6] In these systems, to achieve specific and targeted delivery, the surface of 39 
nanomaterials are often modified with certain targeting ligands, including antibodies, peptides, 40 
small molecules and so on, which have strong affinity with the receptors of targeted cells. 41 
Different from chemical approaches, physical methods usually simply disrupt the cell 42 
membranes to increase their permeability, thus facilitating gene or drug intracellular transport. 43 
Modern physical tools can be tailored to precisely deliver molecules into specific areas of cells 44 
with nano-size resolution, or designed to be suitable for high-throughput intracellular delivery. 45 
Herein, we will review a variety of micro- and nanotechnologies with focus on receptor 46 
mediated intracellular delivery and advanced physical platforms for transporting materials to 47 
cells. 48 
 49 
2. Receptor-mediated endocytosis of nanomaterials for drug delivery 50 
Nanomaterials have been playing important roles in biology and medicine, offering a wide 51 
variety of new strategies for biomedical applications including drug delivery[7,8] and gene 52 
therapy.[9-11]With nanomedicines, drug molecules can be better delivered to tumors in cancer 53 
therapy due to passive targeting phenomenon, also known as the enhanced permeation and 54 
retention (EPR) effect. To further improve the targeted delivery efficiency and extend the 55 
application scopes to other diseases, active targeting is generally employed as well by attaching 56 
specific ligands (e.g., antibodies, peptides and small molecules) to nanomaterials to recognize 57 
and selectively bind to specific cell receptors which are overexpressed on certain cell surface 58 
such as tumor cells.[12] For these reasons, design of new nano-platforms is of great significance 59 
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to advance targeted drug-delivery systems and cancer theranosis. To improve the design, it is 60 
imperative to firstly understand how targeted delivery is achieved through the aid of receptors. 61 
 62 
2.1. Pathways of receptor-mediated endocytosis 63 
The concept of receptor-mediated endocytosis was first put forward by Goldstein and Brown 64 
in 1974. It was observed that the binding of the low density lipoproteins (LDL) to human 65 
fibroblasts exhibits two different affinities, which was explained due to the specific receptor on 66 
fibroblast cell surface.[13] Nowadays, receptor-mediated endocytosis has been well recognized 67 
as a main route through which animal cells internalize ligands and macromolecules.[14,15] 68 
Endocytosis occurs constitutively in all mammalian cells and plays fundamental roles such as 69 
nutrient uptake, iron transportation and intracellular communication. Typically, nanomaterials 70 
transport through the cell membrane via four endocytic pathways including phagocytosis, 71 
macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated endocytosis (Figure 72 
1).[15,16] Among these pathways, clathrin-mediated endocytosis via specific receptor-ligand 73 
association is the best described mechanism. Previously, “receptor-mediated endocytosis” was 74 
referred to this pathway only. However, recently, an alternative non-specific endocytosis via 75 
clathrin-coated pits was also demonstrated.[17] 76 
Clathrin-mediated endocytosis initiates when ligands bind to receptors on the cell surface 77 
and then the receptor/ligand complexes slide laterally into clathrin-coated or smooth pits. The 78 
coated pits are uniquely featured by protein clathrin. In opposite to this, smooth pits are lack of 79 
clathrin coating. Next, the pits bud into the cell and form primary endosomes where the ligand 80 
and receptor can separate. After internalization, the endosomal compartments continuously 81 
acidify from the original neutral pH (∼7) on cell surface to pH (~4) in lysosomes. After 82 
membrane shaping into early endosomes, several primary endosomes fuse to form larger 83 
vesicles while the clathrin coating is shed. These larger vesicles are characterized by a unique 84 
morphology with a main vesicular and multiple tubular compartments. Usually, but not in all 85 
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cases, the detached ligands are carried to lysosomes for degradation, while the receptors cycle 86 
back to the cell surface to selectively recognize and bind new ligands.[18-21] 87 
 88 
2.2. Receptors for targeted delivery of nanomedicines 89 
A rapidly growing tumor requires a large amount of vitamins, essential trace elements and 90 
nutrients. Thus, cancer cells overexpress a wide range of tumor-specific receptors, which can 91 
be applied as targets to particularly deliver therapeutic drugs and imaging agents into tumors.[22] 92 
Currently, more than 25 specific targeting ligands have been noticed to involve in receptor-93 
mediated endocytosis.[23] For example, antibodies and antibody fragments,[24-26] nucleic acid 94 
aptamers,[27-29] peptides,[30, 31] vitamins,[32,33] and glycoprotein[34, 35] have been considered as 95 
tumor-specific moieties to construct “guided molecular missiles”.[36] These targeting receptors 96 
serve two purposes. One is to increase the likelihood that nanomaterials find their way into the 97 
tumor mass via both passive and active targeting and remain within the tumor. The other is to 98 
trigger the transport of the nanomaterials across the cellular membranes in pathological tissue. 99 
Next, we will focus on reviewing various types of cell receptors which can be harnessed for 100 
efficient targeted cancer therapy and early diagnosis. 101 
 102 
2.2.1. Antibodies and antibody fragments 103 
Owing to the high specificity and strong affinity to tumor receptors, mono-antibodies (mAbs) 104 
and their fragments are the most widely used targeting molecules. So far, about 30 of them have 105 
been approved for clinical use. A conventional method of incorporating mAbs and their 106 
fragments to targeting drug delivery systems is to conjugate to nanomaterial surface directly or 107 
through linker molecules.[37] Commonly, the conjugated manner of the antibody to 108 
nanomaterials is random without specific sites, which can be carried out by using carbodiimide-109 
mediated chemistry. This approach is achieved by creating a stable amide bonds between amine 110 
groups in the antibody or antibody fragment and the carboxylic acid groups in nanocarriers.[38] 111 
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Alternatively, another approach is site-specific, realized with maleimide chemistry. Such 112 
binding strategy involves native or pre-designed thiol-containing cysteine residues that locate 113 
away from the antigen binding sites to assure full activity of mAbs and their fragments.[39] In 114 
this part, several most commonly utilized antibody receptors will be stated. 115 
 116 
Epidermal growth factor receptor (EGFR) 117 
The epidermal growth factor receptor (EGFR) is a type of single-chain trans-membrane protein 118 
receptor overexpressed in most epithelial cancer cells and fulfills crucial physiological roles 119 
including binding epidermal growth factor (EGF) and activating multiple signaling pathways 120 
and intracellular communications.[40] The EGF-EGFR interaction is among the first studied 121 
growth factor ligand-receptors.[41] Through the signaling pathway, EGF-EGFR can have a great 122 
influence in regulating cell proliferation, differentiation, and survival.[42,43] In recent years, due 123 
to the overexpression of EGFR found in various types of cancer cells, many approaches have 124 
been developed for designing receptor-mediated targeted drug delivery systems for cancer 125 
detection and treatment.[44] Nie et al. put forward an EGFR targeted multifunctional 126 
nanoparticles for drug delivery and in vivo dual-model imaging. As shown in Figure 2a, 127 
schematic illustration of quantum dots (QDs) functionalized with an amphiphilic polymer and 128 
then conjugated with ScFvEGFR targeting molecules. Figure 2b reveals the highly selective 129 
internalization between cancer cells presenting high level of EGFR (MDA-MB-231 cell) and 130 
low level of EGFR (MCF-7 cell). Although both cell lines were incubated with ScFvEGFR-131 
QDs, obviously strong red fluorescence appears in EGFR over-expressed MDA-MB-231 cells 132 
while only very weak red signals are in EGFR down-expressed MCF-7 cells. Likewise to the 133 
MCF-7 group, a very low level of red fluorescence was observed in the group of cells with high 134 
EGFR expression but incubated with QDs possessing no ScFvEGFR modification. 135 
These results are convincing evidences that ScFvEGFR-conjugated nanoparticles have good 136 
potential in tumor imaging application.[45] 137 
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 138 
Vascular endothelial growth factor receptor (VEGFR) 139 
Both tumor hypoxia and angiogenesis can upregulate expression levels of vascular endothelial 140 
growth factor (VEGF) in tumor cells, thus resulting in a corresponding overexpression of 141 
vascular endothelial growth factor receptor (VEGFR) on tumor endothelial cells. The VEGFR 142 
is regarded as the most relevant persuader in tumor angiogenesis.[46] There are two kinds of 143 
endothelium-specific receptor associated with angiogenic actions: VEGFR-1 and VEGFR-2. 144 
VEGFR-1 is responsible for physiologic process, in particular the angiogenesis development, 145 
and its function may be affected by many factors, such as different developmental stages, tumor 146 
cell types and various physiologic and pathologic conditions; VEGFR-2 is critical to mediate 147 
mitosis, angiogenesis, and permeability-enhancement and simultaneously plays a pivotal role 148 
in tumor progression.[47] Zhang and co-workers demonstrated that nanostructured lipid carriers 149 
(NLC) loaded with chemotherapeutic drug docetaxel and fluorescein FITC exhibit much 150 
superior antitumor cytotoxicity against B16 cancer cells if the nanomaterials are modified with 151 
anti-VEGFR-2 antibody.[48] Figure 2c shows the schematic representation of the NLC carriers 152 
and their fluorescence microscopy images. A relatively stronger green fluorescence is observed 153 
in cells incubated with antibody modified NLC (tNLC) whereas much lower fluorescence 154 
intensity can be detected in cells treated with non-targeted NLC (nNLC). In vivo anti-tumor 155 
experiments verified again the high targeting ability of the modified nanocarriers, as exhibited 156 
in Figure 2d, thus rendering the tNLC with the best efficiency of cancer treatment. 157 
 158 
Prostate-specific membrane antigen (PSMA)  159 
Prostate-specific membrane antigen (PSMA) is a kind of type II transmembrane glycoprotein 160 
produced by prostatic epithelium and with 100 kDa molecular weight and 750 amino acids. The 161 
expression of PMSA is mostly upregulated in prostate cancers and participates in membrane 162 
recycling, tumor metastasis and tumor aggressiveness. However, the expression of this antigen 163 
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has also been found in normal and extraprostatic tissues, such as small bowel, lymph node and 164 
bone metastases.[49,50] Due to the highest PSMA expression related to high-grade tumor, PSMA 165 
could be clinically used as a specific ligand for targeting to metastatic and malignant tumors in 166 
vivo.[51] Anti-PSMA antibodies modified nanomaterials are the most wildly developed PSMA-167 
involved approach for targeted therapeutics and diagnostics. Up to now, many antibodies have 168 
been approved for clinical use, such as J59, 7E11-C5 and MDX-070.[51] As one example, Pang’s 169 
group developed dual-targeted nanoparticles for highly specific prostate cancer therapy.[52] In 170 
this work, they prepared paclitaxel (PTX) loaded superparamagnetic nanoparticles (SMNPs) 171 
and then conjugated with the anti-PSMA antibodies (APSMAs) by a PEG linker (termed as 172 
PTX-HMNC-EPEG-APSMA). As described in Figure 3a, these nanoparticles can be actively 173 
guided to tumor tissue by an external magnet. Then, the nanoparticles are capable of entering 174 
prostate tumor cells via receptor-mediated endocytosis. This dual-targeted strategy dramatically 175 
increases the local concentration of PTX in tumor and intracellular delivery to tumor cells, thus 176 
providing a much specific and highly effective inhibition of tumor growth (Figure 3b). Their 177 
work offers a bright blueprint for human prostate cancer therapy or other metastatic and 178 
malignant tumors theranosis in clinic. 179 
 180 
2.2.2. Nucleic Acid Aptamers 181 
Aptamers are a kind of DNA or RNA oligonucleotides which only have one single strand. With 182 
high selectivity and affinity, aptamers can be applied to specifically binding to a wide variety 183 
of biomedical molecules including drugs, proteins, small molecules, and cancer cells.[53] 184 
Compared with antibodies, aptamers have similar targeting capacity to particular molecules and 185 
cells,[54] but on the other hand, they have superior features that make them more intriguing than 186 
antibodies. Firstly, owing to the smaller size, aptamers can afford greater tissue penetration 187 
depths. Secondly, having no immunogenic reactions and high in vivo stability enables them a 188 
good potential for future clinical applications. Thirdly, similar to nucleic acids, with good 189 
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solubility in different solvents and easy synthesis, aptamers can be chemically modified to meet 190 
different needs in individual targeting platforms.[55] In 2013, Tan and his group developed an 191 
aptamers-mediated probe to modify immune cells for recognizing and killing cancer cells.[29] 192 
They designed diacyl lipid-PEG linker-DNA aptamer conjugates and anchored them on 193 
immune cells surface, thus endowing them with specific targeting ability (Figure 3c). When 194 
cancer cells are incubated with the modified immune cells, the cancer cells can be recognized 195 
and ultimately killed. To locate lipid conjugates, a red fluorescent dye (TAMRA) was 196 
conjugated to the oligonucleotides (termed as lipo-Lib-TMR). In Figure 3d, intensive red 197 
signals are only detected on the cell membrane after treatment with lipo-Lib-TMR, indicating 198 
that the successful anchor of as-prepared lipid-DNA probe on cell surface. Figure 3e and 3f 199 
show proper recognition of targeting cells by TD05 aptamers-modified cells. Assembly and 200 
aggregation upon receptor-ligand binding are observed in the TD05-treated Ramos cells, 201 
whereas no cell-aptamer-cell assembly is found after treatment with lipo-lib-TMR. The above 202 
results demonstrate that membrane-anchored aptamers can selectively trigger cellular adhesion 203 
and this strategy provides an opportunity for achieving cell-based targeted delivery and therapy. 204 
 205 
2.2.3. Peptides 206 
As discussed above, antibodies and aptamers are widely utilized as escort molecules for targeted 207 
delivery of nanomaterials. However, both of them possess several unfavorable drawbacks. First, 208 
mAbs are difficult to achieve large scale manufacture due to batch-to-batch variations and 209 
complicated and expensive preparation process. Moreover, utilization of targeted mAb 210 
nanomaterials is limited by large antibody size, thus leading to worse ability to penetrate tissue 211 
as well as much more difficulty in further chemical modification or conjugation to 212 
nanomaterials. Although aptamers have better properties than mAbs, the potential nuclease 213 
degradation can induce rapid blood clearance and has aroused widespread concerns. Therefore, 214 
alternative small-sized ligands with high stability, such as peptides, have attracted considerable 215 
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attention and substantial research.[56] Peptides are particularly well suited for targeting 216 
nanomaterials because of their fascinating merits consisting of low cost, low immunogenicity, 217 
high affinity to targets, easy to synthesize\handle and long-term storage.[57] Furthermore, their 218 
small size has negligible influence on the optimized physicochemical properties of 219 
nanomaterials.[58] These superior properties make peptides as excellent targeting molecules for 220 
drug delivery and biomedical imaging.  221 
 222 
αvβ3 integrin 223 
Integrin belongs to the membrane spanning receptors, which has a great influence on cell 224 
signaling to operate cell shape, motion and division. Meanwhile, they are also important players 225 
to mediate the association of a cell to surrounding extracellular matrix (ECM) proteins.[59] 226 
Accordingly, the αvβ3 integrin receptors have a direct effect on human metastasis and tumor 227 
angiogenesis. More interestingly, the αvβ3 integrin receptor based targeting probe could be 228 
bound to both tumor vasculature and tumor cells because αvβ3 integrin is upregulated on both 229 
of these two places in many animal models.[60] Arg-Gly-Asp (RGD) peptide having three-230 
amino-acid sequence possessesa high avidity for selective binding to αvβ3integrin receptor. 231 
Therefore, RGD peptide and its derivatives have been extensively developed for site-specific 232 
tumor theranosis in recent years.[41] In 2013, Angelo and co-workers explored the iso Arg-Gly-233 
Asp (iso DGR)-conjugated human serum albumin (HSA) as a new αvβ3 selective vehicle for the 234 
delivery of drugs to tumors.[30]Iso DGR is a derivative of Arg-Gly-Asp (RGD), which can 235 
recognize RGD-dependent integrins with different affinity and specificity.[61] Owing to the high 236 
selectivity for tumor vessels, iso DGR-conjugated HSA might be exploited as a novel and 237 
versatile nanomaterial for the tumor vasculature-selective cancer theranosis.[30] 238 
 239 
Cell-Penetrating Peptides for nucleic acid pharmaceuticals (NAPs) delivery 240 
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Cell-penetrating peptides (CPPs), also known as protein transduction domains, is a typical 241 
cationic peptide with abundant lysine and arginine amino acids, providing a better ability to 242 
rapidly translocate into almost any live cells. CPPs can readily deliver a wide range of 243 
membrane-impermeable biological molecules into cells by noncovalent complex formation or 244 
chemical conjugation.[62] This eminent performance endows CPPs with high internalization 245 
efficacy as an attractive carrier for the delivery of various cargos, in particular nucleic acid 246 
pharmaceuticals (NAPs), including short oligonucleotides, plasmids, genes, and small 247 
interference RNAs (siRNA) and their analogues. Apart from the superior membrane-permeable 248 
ability, CPPs are optimal candidates for NAPs delivery owing to their low cytotoxicity and 249 
flexible structural design.[63,64] 250 
Despite CPPs exhibit a promising potential in NPAs delivery for quickly penetrating tissues 251 
and crossing cellular membranes, they are universal transporters being lack of receptor 252 
specificity because of their positive charges, thus hindering their practical in vivo 253 
applications.[65] To address the issue, in the past few years, substantial improvements in 254 
designing and implementing CPPs-based NAPs delivery systems have been continuously 255 
made.[66-68] In 2012, Bhatia et al. constructed a library of tandem CPPs that condense siRNA 256 
into stable tumor penetrating nanocomplex through noncovalent interactions for receptor-257 
specific siRNA delivery.[69,70] Through the assistance of both tumor-specific and cell-258 
penetrating peptides, the nanocomplex may deliver siRNA deep into the tumor site with 259 
enhanced specificity. In 2013, Shen’s group applied transactivator of transcription (TAT) 260 
peptides – a kind of CCPs – to approve a molecular modification strategy for suppressing 261 
nonspecific interactions of CPPs in the blood compartment whereas remotivating their 262 
functions in the targeted tumor cells to enhance their selectivity and specificity (Figure 4a).[68] 263 
As the primary lysine residue amines in CCPs are the main reason of their low specificity, Shen 264 
and co-workers hypothesized that if amidization of the amines in the lysine residue to succinyl 265 
amides, it might block the functions of CPPs and thus inhibit their unnecessary interactions. As 266 
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depicted in Figure 4b, aTAT is the modified form of TAT. When the aTAT-based carrier 267 
permeates into tumor tissue by the EPR effect, these succinyl amides are hydrolyzed upon acid-268 
triggering in the tumor extracellular acidic environment (pH < 7) and then release the pristine 269 
functioning TAT for quick cellular uptake and nuclear targeting. This smart off-on active 270 
targeting vehicle will provide a better opportunity in drug delivery based on CPPs with 271 
significantly enhanced selectivity and specificity.  272 
 273 
2.2.4. Folic acid 274 
Folic acid belongs to the family of vitamin B that is essential elements for cell survival and 275 
proliferation.[41] The folate receptor (FR) is a 38 kDa glycosyl-phosphatidylinositol-settled 276 
glycoprotein expressed on the membrane of many cancer cells.[12] Based on the highly selective 277 
avidity for binding to FR, folate ligands are the most widely explored targets for cancer 278 
therapeutics and diagnostics.[71-73] Beyond that, folate is characterized with many additional 279 
advantages. Firstly, compared to mAbs, small molecules like folic acid are much easier to be 280 
chemically modified and industrially manufactured at a large scale, which is an obvious 281 
advantage for clinical application.[15] Secondly, folate ligands have low cost, negligible 282 
immunogenicity, trivial toxicity, and good stability in long-term blood circulation.[74] There are 283 
two common methods of incorporating folate to drug delivery systems: one is physical 284 
adsorption, and the other is chemical conjugation by linker molecules.[73] Chen’s group applied 285 
the covalent coupling strategy to anchor folic acid on layered double hydroxide (LDH) 286 
nanoparticles for targeted drug delivery with enhanced selectivity and anticancer efficacy.[71] 287 
Figure 4c described the designed strategy of this targeted LDH nanomaterials which loaded 288 
with anticancer drug methotrexate (MTX) and their significantly enhanced cell cytotoxicity was 289 
shown in Figure 4d. Compared with other control groups (FA-conjugated LDH nanoparticles 290 
without MTX, free MTX), FA-conjugated MTX-loaded LDH nanoparticles performed the best 291 
in killing cancer cells, indicating that this novel nanoplatform has practical value in targeted 292 
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drug delivery with high efficacy. Similar strategy has also been used in Lee’s and Lai’s work 293 
to realize the targeted delivery of small organic nanoparticles and polymeric micelles to various 294 
cancer cells.[72, 73] 295 
 296 
2.2.5. Transferrin (Tf) and lactoferrin (Lf) 297 
The transferrins, typically 80 kDa monermeric glycoproteins containing a single polypeptide 298 
chain with rich amino acids, plays significant role in keeping the availability of free iron and 299 
preventing the precipitation of insoluble ferric hydroxide conglomerations by binding, 300 
secluding, and transporting free iron ions in body fluid environment.[75] Although the transferrin 301 
receptor (TfR) appears to be expressed in all nucleated cells because iron is the essential trace 302 
element to all cells in the body, there is upregulation of TfR in neoplastic cells because of the 303 
requirement of high level of iron for angiogenesis and cell growth.[76] Attributed to the 304 
overexpression of TfRs on malignant cells compared to normal ones, transferrin is a very 305 
promising marker for active targeting. Similar to transferrin, lactoferrin (Lf) is also an iron ions-306 
binding glycoprotein belonging to the Tf family and assists iron uptake in mammalian cells.[77] 307 
Recently, lactoferrin receptor (LfR) was demonstrated to undergo transcytotic pathway in the 308 
brain endothelial cells and pass through the blood-brain barrier (BBB) in vitro and in vivo.[78] 309 
Hence, Lf might be exploited for the brain-targeting delivery of therapeutic agents through 310 
circumventing the epithelial and endothelial barriers. Yang’s group prepared two kinds of iron 311 
oxide nanoparticles that attached with transferrin[34] and lactoferrin.[79] The orthotopic C6 312 
glioma xenograft was clearly visualized by these two targeting nanoparticles at 48 hours after 313 
injection. In addition, fluorescence photos affirmed the specific interaction between the 314 
modified nanoparticles and their corresponding receptors on the brain endothelial cells. Gao et 315 
al. developed a type of PEG-coated Fe3O4 nanoparticles covalently modified with Lf and 316 
applied them to act as brain MRI imaging agent both in vitro and in vivo. (Figure 5a)[35] 317 
Representative axial T2* images of rat brains were acquired before and after injection of Fe3O4-318 
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Lf and Fe3O4. The Lf bonded group shows obviously enhanced signal of blood vessels (the red 319 
circles in Figure 5b-b). This suggests that the Fe3O4-Lfnanoparticles can potentially be used as 320 
a brain-targeting delivery vehicle for cancer therapeutics and diagnosis. 321 
 322 
2.2.6. Other receptors 323 
Besides the above described biomarkers, many other ligands have also been identified as 324 
possible targets of nanomaterials for specific drug delivery. These receptors are overexpressed 325 
in particular tumor cells such as matrix metalloproteinases (MMPs),[80,81] polyunsaturated fatty 326 
acids (PUFAs),[36,82] and hyaluronic acid (HA).[83,84] 327 
Matrix metalloproteinases(MMPs), a family of zinc-dependent endopeptidases that 328 
participate in tumor aggression and progression by degrading the extracellular matrix, are 329 
overexpressed in tumor environments.[85] The membrane-type (MT) MMPs are a subset of the 330 
membrane-anchored proteinases and play predominant roles in dividing cancer cells with 331 
relevance for tumor proliferation and metastasis.[86] Thus, MMPs have become attractive targets 332 
for drug delivery and molecular imaging. More interestingly, MMPs not only can be used as a 333 
target but also might be explored for stimuli-responsive drug delivery based on MMP-cleavable 334 
peptide linkage because the MMP enzyme is up-regulated in tumor tissue.[87] Huh and Haam’s 335 
groups designed a MT1-MMP-targetable magnetic nanoprobe conjugated with an activatable 336 
fluorogenic peptide to precisely recognize the expression of MT-MMPs presented on invasive 337 
cancer cells and their enzymatic activity.[81] In 2014, Zhang et al.developed anticancer drug 338 
doxorubicin (DOX) and plasmid DNA co-loaded graphene oxide (GO)-based nanohybrid for 339 
responsive drug delivery and cancer combination therapy.[88] First, DOX was chemically 340 
conjugated to GO via a MMP2-cleavable peptide linkage. When the nanohybrid reaches the 341 
MMP2-overexpressed tumor sites, the peptide linkage cleaved and subsequently released the 342 
drug as well as recovered the red fluorescence of DOX. This tumor triggered theranostic 343 
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strategy could open a new window for highly efficacious cancer combination therapy merging 344 
the targeting and bio-responsive capability. 345 
Plyunsaturated fatty acids (PUFAs), possessing 18, 20, and 22 carbons and 2-6 cis double 346 
bonds in their backbone, are ideal candidates for tumor-specific drug delivery because they can 347 
be taken up cushily by tumors from the blood.[89] In particular, docosahexaenoic acid (DHA) is 348 
the most widely employed fatty acid as a guiding molecule approved by Food and Drug 349 
Administration (FDA), which is a basic constitute of cell membranes in the brain and other 350 
capillary endotheliums.[90] DHA-paclitaxel conjugate has already been synthesized and used in 351 
active tumor targeting. The antitumor activity in mice was exceedingly increased when 352 
compared with paclitaxel without DHA modification.[82] 353 
Hyaluronic acid (HA) is an anionic linear polysaccharide and serves a variety of functions 354 
within the extracellular matrix. Owing to their low cost, negligible toxicity, good 355 
biocompatibility and abundant expression in most malignant solid tumors, HA has attracted 356 
intensive attention for application in targeting of anticancer agents with enhanced binding and 357 
internalization.[91] In a recent work, Bissell and co-workers made use of a fluorescent HA to 358 
observe distinctive attaching patterns to HA receptors CD44 and RHAMM. This quantitative 359 
approach not only reveals the heterogeneity of breast cancers, but also may be applicable to 360 
other ligands/receptors.[92] 361 
Apart from these described ones, many other receptors including human epidermal 362 
receptor-2 (HER-2),[26, 93] low-density lipoprotein receptors (LDLR),[94, 95] vascular cell 363 
adhesion molecule-1(VCAM-1),[96, 97] and interleukin (IL) receptors[98, 99] have also been 364 
employed in a variety of nano-drug delivery systems for an extensive variety of applications. 365 
 366 
2.3. Two (or more) order targeting of nanomaterials for drug delivery 367 
As reviewed above, nanomaterials conjugated with a wide range of pertinent tumor-binding 368 
markers have been utilized to actively target malignant cells via specific receptor-ligand 369 
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interaction. The surface receptors of tumor cells vary both spatially and temporally, express 370 
differently from each other in the same tumor. Unfortunately, most receptors are only 371 
overexpressed in certain cells, targeting a single surface receptor results in uncontrollable and 372 
variable targeting delivery efficiency and thus the outcome of the single-targeting approach 373 
seems to be limited. Multidrug resistance (MDR) is a major factor in the failure of many forms 374 
of cancer chemotherapy. In particular, P-glycoprotein (P-gp) is well known to be an important 375 
drug efflux pump, which usually results in drug resistance. To overcome this problem, 376 
attractively, several recent works have showed that a dual-targeting approach can be a better 377 
option for targeted delivery and MDR reversal.[100,101] In 2014, He et al. developed folate and 378 
CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric 379 
micelles for overcoming multidrug resistance and improving tumor distribution.[101] The two 380 
(or more) order targeting has also been utilized in crossing the blood-brain barrier (BBB) in 381 
vivo. Li et al. developed a two-order targeted strategy to vastly improve nanoparticles’ 382 
localization and visualization in U87MG glioblastoma xenograft (Figure 5d).[102] In this 383 
approach, a novel type of dual-modal imaging and two-order targeted PAMAM-G5 dendrimer 384 
nanoparticles was designed. In the system, Gd3+-DOTA chelators and fluorophore Cy5.5 were 385 
employed for MIR and NIR imaging, respectively. At the same time, cyclic [RGDyK] peptides 386 
were for targeting tumor vasculatures where αvβ3 integrin is over-expressed, and Angiopep-2 387 
peptides for facilitating the delivery of the nanoparticles across BBB. As presented in Figure 388 
5c, dendrimer nanoparticle first binds to tumor neovasculatures that are sounding tumor 389 
periphery, and then targets to the αvβ3 integrin and LRR receptor thus leading to crossing the 390 
BBB and finally entering into brain tumor cells by the second targeting. Subsequent in vivo 391 
MIR and NIR imaging of U87MG tumor (Figure 5e) indicates the feasibility of using dual-392 
modal nanoparticles to locate and visualize brain tumor with high specificity. In the near future, 393 
we believe that the development of two (or more) order targeting nanomaterials holds great 394 
promise for highly specific drug delivery and imaging. 395 
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 396 
2.4. Target delivery to specific subcellular action sites 397 
In this section, we mainly focused on using targeting ligands to help drugs to achieve specific 398 
delivery to disease cells. Compared with free drugs, the nanomedicines are able to more 399 
efficiently to penetrate the cell membranes and enter into the cytoplasm. However, most of the 400 
intracellular localization of nanoparticles are observed in the cytoplasm and rarely in the cell 401 
nucleus. In fact, the cell nucleus is the final targeting site because it is the cellular “heart”, which 402 
contains the genetic information and where various therapeutic agents efficiently work. 403 
Typically, the aim of gene therapy is to correct disfunctional genes by delivering therapeutic 404 
genes into the cell nucleus. In addition, certain anticancer drugs such as doxorubicin, 405 
camptothecin and cisplatin need to diffuse to nucleus for taking effective function because 406 
nucleus is their targets. To further improve the efficacy of these types of drugs and help them 407 
to target specific subcellular action sites, various approaches have been developed. For example, 408 
Parang’s group reported several nuclear-targeting cyclic peptides such as [WR]4 and [WR]5 to 409 
form a complex with the cargo for directly transporting doxorubicin to nucleus. [WR]4 and 410 
[WR]5 are a kind of cyclic cell-penetrating peptide with nuclear targeting and non-covalent 411 
molecular transport capabilities. [103] In another work, Shi et al. developed TAT peptide-412 
conjugated monodisperse mesoporous silica nanoparticles with high loading of doxorubicin for 413 
nuclear-targeted drug delivery. TAT peptide is an efficient ligand for translocating 414 
nanomaterials into cell nucleus through the binding import receptors and subsequently entering 415 
their nucleus. [104] Both of aforementioned nuclear-targeted drug delivery systems showed a 416 
significant enhancement in anticancer activity of doxorubicin because nuclear-targeted drug 417 
delivery strategy is expected to kill cancer cells more directly and efficiently. 418 
 419 
3. Physical approaches for intracellular delivery 420 
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Different from chemical approaches, physical platforms are mechanically interacting with the 421 
cell membranes and thus enhance membrane permeability to achieve improved intracellular 422 
delivery. In the following part, the advancement of a number of traditional physical approaches 423 
including electroporation, sonoporation, and biolistics will be summarized. Additionally, 424 
emerging techniques using nanoneedle/nanowire arrays for high-throughput intracellular 425 
delivery will be highlighted. 426 
 427 
3.1. Electroporation 428 
Electroporation is to use short high-voltage electric pulses to reversibly disrupt cell membranes 429 
for delivery of wide range of molecules.[105] It is one of the most commonly used approaches in 430 
the past decades. This technique was initially developed for gene transfer and later the usage 431 
was extended to a wide variety of molecules. Under short high-voltage electric pulses, pores 432 
created on the cell membranes allow molecules to diffuse into cells. Only when transmembrane 433 
potential exceeds a threshold, electroporation aided intracellular delivery can be achieved.  434 
Transmembrane potential is described by equation:  435 
ΔVm=fEext r cosФ                                  (1) 436 
Where Vm is the transmembrane potential, f a form factor of extracellular field distribution, 437 
Eext the applied electric field, r the cell radius and Ф the polar angle with respect to the external 438 
field.[105] 439 
Neumann et al. introduced this technique in 1982 to deliver DNA into viable mouse lyoma 440 
cells by a high electric field.[106] In this study, electric impulses (8 kV/cm, 5 μs) were applied 441 
to mouse lyoma cells. After three successive electric impulses, 95 ± 3 transformants per 106 442 
cells DNA were found at a dose of 1.2 μg of DNA. This study initiated a simple physical model 443 
for enhanced DNA intracellular delivery with high electric field. In 1980s, in vitro 444 
electroporation was widely employed for the delivery of human kappa immunoglobulin genes 445 
into mouse pre-B Lymphocytes,[107] plasmid DNA and antisense RNA into plants cells,[108, 109] 446 
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and DNA to bacterial cells[110, 111]. From 1990s, electroporation was broadly investigated for in 447 
vivo applications[112]  in muscle,[113] skin,[114] liver[115] and tumors[116,117] and successful 448 
intracellular delivery was demonstrated. Currently, electroporation has been very commonly 449 
used. Compared with the platform at 20 years ago, modern electroporation possesses improved 450 
deliver efficiency, reduced operation time, and increased cell survival rate and precision. For 451 
example, Saito et al. reported in vivo high efficiency and fast transfection of nervous systems 452 
by electroporation.[118] In their study, over ten embryos were conducted within 30 minutes and 453 
the survival and transfection rates were all greater than 90%. Geng et al. described a novel flow-454 
through electroporation method for gene delivery.[119] Compared with conventional 455 
electroporators working in bath mode and being limited by performing on only small amounts 456 
of samples (about 1 mL in volume) each time, this modified approach can continuously deliver 457 
gene into Chinese hamster ovary (CHO-K1) cells in a high-throughput way (up to about 458 
20mL/min) with a high transfection efficacy of 75%. Boukany et al. further combined 459 
electroporation with nanotechnologies and introduced a type of nanochannel electroporation, 460 
which can deliver precise amount of biomolecules into living cells with minimal cell 461 
damage.[120] This device includes two microchannels (cell in one side and reagent in the other 462 
side) that are linked with a nanochannel. When high voltage pulses are applied between the two 463 
microchannels, a limited area of cell membrane is affected by intense electric field, thus 464 
allowing very precise amount of biomolecules into cytoplasm. Overall, electroporation offers 465 
many great advantages including 1) high efficiency for gene and other biomolecules 466 
intracellular delivery, 2) minimal safety concerns, 3) cell type independency. However, 467 
electroporation requires very complicated pulse generators to produce short high-voltage 468 
electric pulse and expertise is needed for equipment handling. 469 
 470 
3.2. Sonoporation 471 
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Sonoporation is an approach to facilitate intracellular delivery by applying ultrasound. High-472 
amplitude acoustic wave induced cavitation is considered as the main mechanism of 473 
sonoporation for intracellular delivery. Stable cavitation and transient cavitation are two typical 474 
cavitation forming modes.[121] The former is the stable oscillation of encapsulated gas bubbles, 475 
inducing shear forces to disrupt cell membrane and leading to allow drug/gene delivery. The 476 
latter is caused by collapse of bubbles which generate shock waves to facilitate intracellular 477 
delivery. Sonoporation is a reversible and non-destructive process. Cells can recover their 478 
membranes within a few seconds after ultrasound exposure.[122] Although ultrasound has been 479 
used for diagnosis for many years, its applications for gene delivery just started in mid-1990s. 480 
Kim et al. and Bao et al. reported successful in vitro transfection of plasmid DNA with help of 481 
ultrasound.[123, 124] Later, ultrasound was used for in vivo naked DNA delivery. For example, 482 
skeletal muscle,[125] carotid artery,[126] kidney,[127,128] and heart[129] were tested with successful 483 
DNA transfection using ultrasound.[130] Besides gene delivery, ultrasound was also used for 484 
transdermal drug delivery. For example, ultrasound can increase the permeability of skin by 485 
disrupting stratum corneum lipid structure, thus facilitate drug/biomolecules penetrate into skin 486 
tissue.[131] Generally speaking, there are two kinds of approaches for local drug delivery using 487 
sonoporation.[131] One is to use micro- and nanobubbles to help to create cavitation on the cell 488 
membranes and disrupt blood vessels, thus increasing permeability of certain cells and 489 
facilitating drug localization in tumors. The other is to directly load drug into microbubbles. In 490 
this approach, ultrasound induced microbubbles collapse to not only create cavitation, but also 491 
trigger release of drug molecules to ultrasound treated cells. Ultrasound is shown to be 492 
promising for cancer tumor treatment. Drug/gene encapsulated carriers can be injected into 493 
mouse and pulsed focused ultrasound is subsequently applied to tumor tissues for triggering 494 
drug release or improving drug delivery by destructing micro- and nanobubbles.[132] For 495 
example, Lin et al. reported enhanced tumor deposition of lipid-coated CdSe quantum dot with 496 
aid of ultrasound and an ultrasound contrast agent.[133] In this study, an ultrasound contrast agent 497 
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(microbubbles) was intravenously injected followed by ultrasound application to tumors. Then 498 
lipid-coated CdSe quantum dots were injected. The results demonstrate that the application of 499 
ultrasound and microbubbles is able to enhance drug delivery into the tumors possibly by 500 
increasing vascular permeability.[133] Suziki et al. reported a type of liposomal nanobubbles 501 
with size of 500 nm for dramatically enhanced plasmid DNA (interleukin-12 corded plasmid 502 
DNA) delivery and correspondingly an effective gene therapy for cancer treatment.[134] Other 503 
than using micro- and nanobubbles purely as a cavitation generation medium, Yang et al. 504 
presented using Fe3O4 nanoparticles loaded microbubbles for controlled release to tumor cells 505 
through sonoporation. Through this approach, the nanoparticles can be effectively delivered 506 
into tumor cells with a noninvasively way through help of ultrasound, and the delivery rate can 507 
be controlled by acoustic intensity.[135]  Moreover, focused ultrasound is able to successfully 508 
create blood-brain barrier disruption (BBBD) without neuron damages,[136] through which 509 
chemotherapy agent or antibody, like Doxorubicin and Herceptin, can nan-invasively transport 510 
into rat brain with increased local concentration.[137,138] Most recently, Ting et al. fabricated 511 
anticancer drug 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU) loaded microbubbles and found 512 
that the nanomedicine improves local BCNU deposition in brain tissue under focused 513 
ultrasound. In vivo study shows the BCNU loaded microbubbles can effectively inhibit tumor 514 
growth (tumor size of 11.0 ±1.0 mm3 in comparison with control group of202±24.10 mm3).[139] 515 
 516 
3.3. Biolistics 517 
Biolistics (also called as gene gun) is a method to inject cells with very high speed heavy metal 518 
particles coated with DNA for gene delivery.[122] This technique was introduced by Klein et al. 519 
in 1987 for gene transfection of plant cells.[140] In the study, accelerated small tungsten particles 520 
carrying RNA/DNA pierced cell walls and membranes and penetrated into intact plant cells 521 
without noticeable cell death.[140] In early 1990s, this approach was extended to mammalian 522 
cells and also liver and skin tissue in living mice.[141, 142] The studies proved that biolistics is 523 
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effective with a wide range of isolated cells and tissues. O’Brien et al. used a hand-held gene 524 
gun and realized successful transfection of cultured human embryonic kidney (HEK) 293 cells 525 
and organotypic brain slices.[143] Although many studies reported biolistics method can deliver 526 
gene and transfect cells in many organs (e.g., muscle, liver, heart and brain), the major 527 
application is transdermal delivery because its low tissue penetration capacity.[130] 528 
Rakhmilevich et al. reported gene gun-mediated skin transfection of interleukin 12 can 529 
effectively inhibit tumor growth.[144] In their study, detectable level (266.0 ± 27.8 pg) of 530 
transgenic protein was found at treated skin sites. This method was able to completely regress 531 
the established tumors in the treated mice. In biolistic delivery, particles can penetrate the outer 532 
layer of skin and reach the epidermal layer rich of antigen presenting cells, thus maximizing 533 
immunization efficiency. Larregina et al. reported transfection of human skin organ cultures 534 
with antigen expression in resident cutaneous dendritic cells by biolistics.[145] They also found 535 
the particles are primarily in epidermis, and Langerhans cells can be successfully transfected. 536 
Hung et al. tested delivery of several DNA vaccines through biolistics method for cervical 537 
cancer vaccination.[146] Beyond heavy metal nanoparticles which may cause adverse side effects, 538 
a number of types of biodegradable polymeric nanoparticles were also chosen for biolistic 539 
applications. Lee et al. developed a biodegradable and non-toxic polymeric nanoparticles 540 
composing of chitosan and poly-γ-glutamic acid for transdermal DNA delivery with help of 541 
low pressure gene gun.[147] The results indicated good penetration depth was obtained in mouse 542 
skin and in vivo gene expression was realized. Despite of the great potential of biolistics for 543 
transdermal gene delivery, this technology is seriously limited by several shortcomings: 1) 544 
high-cost of equipment, 2) high cell damage and death, 3) variation of skin properties.[148] 545 
 546 
3.4. Nanoneedles/nanowires 547 
Microinjection was broadly used for delivering exogenous molecules into cells by penetrating 548 
the membranes with minimal perturbation. In 2007, it has be found a single multiwalled carbon 549 
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nanotube attached to an atomic force microscope (AFM) tip can deliver protein coated quantum 550 
dots into living human cells with a nanoscale resolution.[149] This nanotube causes no 551 
discernible membrane or cell damage, and can deliver a discrete number of molecules to the 552 
cell’s interior without the requirement of a carrier solvent.[149] Two years later, Yum et al. used 553 
boron nitride nanotube to deliver fluorescent quantum dots into living cells (Figure 6a, b).[150] 554 
In this study, they demonstrated the selective delivery of monodispersed quantum dots into the 555 
cytoplasm (Figure 6c) or nucleus (Figure 6d) of living cells.[150] After that, Singhal et al. 556 
reported carbon-nanotube based endoscopes for minimally invasive intracellular probing, drug 557 
delivery and single-cell surgery (Figure 6e).[151] This endoscope can very precisely enter 558 
specific area of cells with about 100 nm resolution and also access organelles without disrupting 559 
the cells (Figure 6f). Also this endoscope is able to transport nanoparticles and attoliter volumes 560 
of fluids to and from precise locations with a minimal invasive way.[151] Although these 561 
approaches can effectively deliver molecules/particles with ultrahigh precision, the technique 562 
can treat only very low number of cells at one time and not applicable for mass intracellular 563 
delivery of drugs/molecules. This drawback seriously limits this technique for future clinical 564 
applications. 565 
To achieve high-throughput intracellular delivery, Kim et al. first demonstrated applying a 566 
silicon nanowire (SiNW) array for this purpose. In the technique, mammalian cells such as 567 
mouse embryonic stem (mES) cells and human embryonic kidney (HEK 293T) cells were 568 
cultured on the top of SiNWs pre-coated with DNA (Figure 7a-b).[152] Through the study, they 569 
observed that the cells could be pierced by the SiNWs and gene transfection of HEK 293T cell 570 
line was achieved. However, a low transfection efficiency, less than 1%, was obtained. Shalek 571 
et al. later demonstrated SiNWs can penetrate the cell membranes and subsequently release the 572 
surface-bound molecules directly into cell’s cytosol.[153] It was also found that this modality 573 
can deliver a wide range of molecules for versatile applications including delivery of small 574 
molecules for guided neuronal progenitor growth, siRNAs for gene silence, and peptide for 575 
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inhibiting apoptosis. With this method, a large number of cells can be cultured on SiNWs at the 576 
same time. Therefore this platform can introduce a diverse range of biomolecules to living cells 577 
in high-throughput way without need of chemical modification and viral packaging. Recently, 578 
Melosh and co-workers developed alumina hollow nanostraw arrays(Figure 7c).[154] The 579 
nanostraws (nanotubes) can penetrate the cell membranes during cell culture on top of them. 580 
Then protein/genetic molecules can be injected into the cells through an integrated device, as 581 
shown in Figure 7d. Later on, the same group equipped the nanostraw array together with 582 
electroporation platform. With help of electroporation, highly efficient molecule delivery and 583 
high transfection yields with excellent uniformity and cell viability were achieved.[155] In the 584 
two studies, they found hollow nanostraw platform can offer high efficiency and excellent 585 
spatial, temporal and dose control for biomolecules delivery. Chan et al. reported vertical 586 
silicon nanoneedle arrays to transfer intact 3D DNA nanocages directly to cytoplasm without 587 
endocytosis.[156] Same as others, they also found this approach offers high gene delivery 588 
efficiency and low cell toxicity. Most recently, Melosh and co-workers demonstrated the hollow 589 
nanowires (or nanostraw) can directly penetrate membrane by observing dynamic ion delivery. 590 
They found that 7.1±2.7% of the overall nanostraws penetrated into cells and 10.7±5.8 591 
nanostraws pierced each individual cell.[157] Generally speaking, nanowires are commonly 592 
considered as a useful tool for interfacing living cells with minimal cellular perturbation. 593 
However, culturing cells on silicon nanowire arrays might have influences. For example, 594 
mesenchymal stem cells cultured on silicon nanowire show significantly different behavior of 595 
adhesion, proliferation and differentiation, comparing with flat silicon or control substrates. 596 
This interaction between mesenchymal stem cells and SiNWs can induce the stem cells 597 
differentiating toward osteocytes and chondrocytes instead of adipocytes in the absence of 598 
supplementary growth factors.[158] In addition, Persson et al. reported fibroblasts cultured on 599 
nanowires exhibiting low motility, impaired cell division and DNA damage.[159] They found 600 
highly curved but intact nuclear membranes, indicating no direct penetration into nuclei. DNA 601 
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damage may be induced by reactive oxygen species (ROSs) which were triggered by cellular 602 
stress and high respiration rates.  603 
Different from culturing cells on nanowire or nanostraw arrays, we designed a novel 604 
approach using nanoneedle arrays to actively and mechanically disrupt cell membrane for 605 
intracellular delivery.[160] The principle of this approach is similar with employing microneedle 606 
arrays to pierce the stratum corneum for transdermal drug delivery. Transdermal delivery is 607 
using microneedle to penetrate stratum corneum to facilitate vaccine/drug diffusion.[161,162] To 608 
avoid irreversible damage to cells but maintain high intracellular delivery efficiency, we 609 
decided to fabricate nanoneedles with diameter of 100-400 nm. To ensure the nanoneedles have 610 
enough mechanical strength to pierce the cell membranes when the diameters are so small, we 611 
selected diamond, the hardest material in nature, to make robust nanoneedle arrays.[163] The 612 
diamond nanoneedle array was fabricated by depositing a layer of diamond film on a silicon 613 
substrate followed by bias-assisted reactive ion etching (RIE). The prepared diamond 614 
nanoneedles have distal tip diameter of 135 ± 20 nmand length of 7.42 ± 1.35 μm (Figure 8a). 615 
Different from others’ culturing of cells on nanowires or nanostraws for passive penetration 616 
into cells for intracellular delivery, we applied cell suspension onto the diamond nanoneedles 617 
for active disrupting the cell membranes within extremely short period of interaction time. 618 
Figure 8c-e clearly demonstrates that dramatically improved intracellular delivery of 619 
luminescent iridium (III) polypyridine complex when the cells were treated with nanoneedles. 620 
Very attractively, direct nucleus delivery of molecules was confirmed to be achievable. Beyond 621 
facilitating delivery of fluorescent molecules to cells, nanoneedle arrays can also greatly 622 
enhance the delivery of biologically functional molecules to cells and increase their therapeutic 623 
efficacy (Figure 8f). With similar strategy, high density diamond nanocone arrays (200 nm to 624 
1 μm of height and 10 nm of tip radii) were shown to facilitate intracellular delivery of 625 
differentiation medium to a great number of MC-3T3 cells and therefore speed up the 626 
proliferation of the cells, which is potentially useful for early bone formation.[164] Besides 627 
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intracellular delivery, there are many other applications of nanowire/nanoneedle arrays. For 628 
example, Robinson et al. reported vertical nanowire electrode arrays can allow interfacing 629 
multiple mammalian neurons, intracellularly record and stimulate neuronal activity, and map 630 
multiple individual synaptic connections.[165] Xie et al. presented intracellular and extracellular 631 
long time recording of action potential of cardiomyocyte, with high signal strength and quality, 632 
using a similar approach.[166] Since 2007, majority of researches has been mainly working on 633 
in vitro applications of nanoneedle/nanowires. In early 2014, Tseng and co-workers reported in 634 
vivo study of substrate-mediated gene delivery, as shown in Figure 9.[167] In their deliver system, 635 
two nanoscale features were included: 1). DNA-SNPs (supramolecular nanoparticles) vector 636 
for gene encapsulation and 2). Adamantane (Ad)-grafted silicon nanowire substrates. In this 637 
research, Adamantane (Ad)-grafted silicon nanowire substrates was subcutabeously 638 
transplanted into one side of mouse body (opposite side without Adamantane (Ad)-grafted 639 
silicon nanowire substrates was considered as control) and gene encapsulated SNP was locally 640 
injected, as shown in Figure 9a. It is found that significantly increased gene expression can be 641 
achieved in presence of Adamantane (Ad)-grafted silicon nanowire substrates. This study 642 
suggests the promising potential of nanowire substrates for in vivo application of intracellular 643 
gene/drug delivery. 644 
 645 
3.5. Physical stimuli aided intracellular delivery and drug release 646 
Besides using electroporation, sonoporation, micro/nano-injection, and nanoneedle arrays for 647 
intracellular delivery, other physical strategies are also available for this purpose by stimuli-648 
triggered delivery. The stimuli can be divided into two parts: internal stimuli and external 649 
stimuli for triggering release. For internal stimuli, local differences of pH, temperature and 650 
redox microenvironment are major potential stimuli trigger factors.[168] For instance, pH values 651 
of solid tumors are much lower (about pH=6.5) than those in blood or normal tissues (pH=7.4). 652 
pH sensitive molecules, like pH (low) insertion peptide (pHLIP), can be used to target acidic 653 
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tumor tissues. [169] Also, further lower pH values can be found in endosome and lysosome during 654 
endocytosis. Such a pH difference is often used for designing pH sensitive vesicles for 655 
increasing intracellular delivery or triggering release in tumor area.[170] In addition, the pH 656 
buffering effect of pH sensitive polymers can help endosome escape by inducing osmotic 657 
swelling and endosome rupture.[171] For external stimuli, magnetic, ultrasound, light and heat 658 
can as well be used for improved intracellular delivery or as a release trigger. For example, 659 
magnetic nanoparticles can carry therapeutic molecules into cells more efficiently and, 660 
attractively, deliver to specific area of interest with the aid of an external magnetic field.[172, 173] 661 
Light responsive nanocarriers can be triggered by near-infrared (NIR) light illumination for 662 
drug release. For example, NIR-responsive mesoporous silica coated upconverting nanoparticle 663 
can release drug by 980 nm light irradiation.[174] Extensive discussion of stimuli-responsive 664 
delivery is beyond the scope of this review, several excellent reviews are available in literature 665 
for further description.[168, 175] 666 
 667 
 668 
4. Conclusion and future outlook 669 
The emergence of micro- and nanotechnologies opens up new opportunities for intracellular 670 
delivery. In this review, we summarized different strategies including chemical and physical 671 
platforms to achieve improved intracellular delivery. In chemical approaches, a broad range of 672 
targeting ligands (antibodies, aptamers, peptides, small molecules, etc.), which have strong 673 
affinity with the receptors overexpressed on particular tumor cells, are modified onto the surface 674 
of nanomaterials for active targeted delivery with high specificity and selectivity. Physical 675 
approaches, including traditional electroporation, sonoporation, and emerging techniques using 676 
nanoneedle/nanowire arrays, can disrupt the cell membranes to enhance its permeability and 677 
facilitate intracellular delivery. These techniques can be tailored for high precision single cell 678 
delivery with resolution within 100 nm or for high-throughput intracellular delivery to millions 679 
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of cells. Substantial progress has already been made, but there is still an urgent need to develop 680 
one individual platform to combine as many as the advantages of different techniques such as 681 
being efficacious, specific, controllable, safe, universal and high-throughput. For clinical 682 
applications, targeting ligands will be the most promising approaches for specific delivery of 683 
drugs to certain types of cells (e.g., cancer cells), as this will lead to tremendous advantages 684 
including improved drug efficacy and reduced side effects. This approach has been used in 685 
clinical applications. For example, many mAb-drug conjugates have advanced to human 686 
clinical trials. A mAb conjugated calcheamicin (Mylotarg) has been approved for clinical 687 
use.[176] In adddition, the DHA conjugated paclitaxel (Taxoprexin) exhibited substantially 688 
increased antitumor activity, reduced systemic toxicity and high stability in blood plasma as 689 
compared to paclitaxel, which has advanced to human phase III clinical trials.[37] Despite of the 690 
great potential, there are also major challenges in systemic administrations of these targeted 691 
nanomedicines. For instance, the toxicity and the clearance of nanomedicines need to be 692 
thoroughly investigated. After taking their functions, nanomaterials are required to be excreted 693 
out from patients relatively quickly. In order to achieve this, one of the strategies is to allow 694 
nanomaterials to decompose immediately after releasing the loaded drugs to specific disease 695 
sites.[177] Another approach is to reduce unnecessary use of drug carriers. For this, carrier-free 696 
drugs are developed. [178, 179] In comparison, the main physical approaches (e.g., electroporation 697 
and nanoneedle) summarized in this review are predominantly for in-vitro studies although they 698 
can also be indirectly used for in-vivo applications. As one example, these physical techniques 699 
may be used to introduce genes to stem cells for subsequent cell therapy for patients. Overall, 700 
we believe that micro- and nanotechnologies will draw a bright blueprint for in vitro and in vivo 701 
drug delivery and further for actual clinical application. 702 
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 968 
Figure 1. Distinct pathways for cargo internalization by cells. 1) Phagocytosis involves surface 969 
receptors and engulfs large particles through envelopment by the plasma membrane. 2) 970 
Macropinocytosis generates large macropinosomes containing extracellular fluid and soluble 971 
protein. 3) Clathrin-dependent endocytosis involves the assembly of clathrin and adaptor 972 
proteins on a region of the plasma membrane in which particular receptors are clustered to form 973 
a nascent vesicle destined for internalization. 4) Caveolin-dependent endocytosis involves the 974 
assembly of caveolin coats on regions of the plasmamembrane rich in particular lipid rafts to 975 
form a nascent vesicle destined for internalization. Reproduced with permission.[15] Copyright 976 
2013, Elsevier. 977 
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 979 
Figure 2.a) QDs were coated with the amphiphilic polymer modified with short PEG chains 980 
and conjugated to Ni-NTA. Recombinant ScFvEGFR protein has a high purity showing as a 981 
single band protein with a molecular weight around 25 kDa. His-tagged ScFvEGFR was 982 
conjugated to QDs through the interaction of nickel with histidine residues located at the C-983 
terminal of the protein. b) Selective internalization of ScFvEGFR-QDs in tumor cells was 984 
determined using cancer cell lines expressing a high (MDA-MB-231) or low (MCF-7) level of 985 
EGFR. Strong red fluorescent signal was detected inside MDA-MB-231 cells incubated with 986 
ScFvEGFR-QDs but not with non-targeted QDs. A very low level of red fluorescence was seen 987 
in MCF-7 cells after incubating with ScFvEGFR-QDs. Cell nuclei were counterstained with 988 
Sytogreen (Invitrogen). Reproduced with permission.[45] Copyright 2009, Wiley-VCH Verlag 989 
GmbH & Co. KGaA, Weinheim. c) Schematic representation of the antibody, FITC-colabeled 990 
nanostructured lipid carriers and fluorescence microscopy images of (A) tNLC and (B) 991 
nNLC.d) Photographs of tumors from each treatment group excised on day 20. Reproduced 992 
with permission.[48] Copyright 2011, American Chemical Society 993 
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 995 
Figure 3.a) The mechanism of action of PTX-HMNC-EPEG-APSMA for targeted cancer 996 
chemotherapy in a magnetic field. b) Quantitative analysis of the effects of various treatments 997 
on tumor size. Values are means (SD (n = 8). Reproduced with permission.[52] Copyright 2012, 998 
American Chemical Society. c) Illustration of targeting cancer cells (blue) with aptamer-999 
modified immune cells (red). After incubating with lipo-aptamer probes (shown in expansion), 1000 
immune cells recognize and kill cancer cells in the cell mixture. d) Confocal microscope image 1001 
of lipo-Lib-TMR-treated CEM cells. Red fluorescent probes were found only on the cell surface. 1002 
Scale bar: 10 mm. e) Ramos cells spontaneously aggregate after treatment with lipo-TD05-1003 
TMR. Scale bar: 100 mm. f) Control experiments showed no assembly when Ramos cells were 1004 
treated with lipo-lib-TMR. Scale bar: 100 mm. Reproduced with permission.[29] Copyright 2013, 1005 
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 1006 
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 1008 
Figure 4.a) Illustration of the use of TAT as an example of a cell-penetrating peptide (CPP) to 1009 
demonstrate the concept of deactivation of a CPP in the blood compartment and its activation 1010 
in the tumor interstitium or cells for in vivo tumor-targeted drug delivery. The amines of the 1011 
lysine residues of a CPP are amidized to inhibit its nonspecific interactions in the blood 1012 
compartment without affecting the nanocarriers’ stealth properties. Once the nanocarrier 1013 
extravasates into tumor tissue through highly permeable blood vessels via the EPR effect, these 1014 
amides are hydrolyzed, regenerating the pristine functioning CPP in the acidic tumor 1015 
extracellular fluids (pH < 7) for fast cellular uptake or in acidic endo/lysosomes for fast 1016 
endo/lysosomal escape and nuclear targeting. b) Amidization of TAT’s primary amines to 1017 
succinyl amides and their acid-triggered hydrolysis. Reproduced with permission.[68] Copyright 1018 
2012, American Chemical Society. c) Overview of FA-conjugated self-assembled LDH 1019 
amorphous nanoparticles. Black arrow shows the TEM image of monodispersed FA-conjugated 1020 
LDH nanoparticles. d) The viabilities of HeLa cells after 48 hours of incubation with FA-1021 
conjugated LDH nanoparticles (NP), free MTX anticancer drug (MTX) and the LDH 1022 
nanoparticles loaded with MTX (NP–MTX). Reproduced with permission.[71] Copyright 2013, 1023 
Royal Society of Chemistry. 1024 
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 1026 
Figure 5.a) Receptor-mediated delivery of PEG coated Fe3O4 nanoparticles were covalently 1027 
bonded with Lf across the Blood-Brain Barrier. b) Axial T2* images of rat brains captured 1028 
preinjection and 15 min postinjection of Fe3O4-Lf and Fe3O4, respectively. The red dashed-line 1029 
circles highlight the brain blood vessels enhanced by the Fe3O4-Lf probe. Reproduced with 1030 
permission.[35] Copyright 2012, American Chemical Society. c) Overview of two-order targeted 1031 
brain tumor imaging strategy. The nanoprobe ﬁrst targets the αvβ3 integrin on tumor 1032 
vasculatures. After binding with nearby LRP receptors, the nanoprobe traverses BBB via LRP 1033 
receptor-mediated transcytosis and finally targets tumor cells directly. d) Schematics of the 1034 
targeted nanoprobes. e) In vivo MIR image and NIR image of U87MG tumor indicated the 1035 
feasibility of dual-model nanoparticles to visualize brain tumor with high specificity. 1036 
Reproduced with permission.[102] Copyright 2012, American Chemical Society. 1037 
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 1039 
Figure 6. Nanoscale mechanochemical delivery of QDs into living cells. (a) Schematic of the 1040 
mechanochemical delivery of QDs into living cells. Inset, optical microscopy image of a typical 1041 
nanoneedle. Scale bar, 5 μm.(b) Optical microscope images of a nanoneedle functionalized with 1042 
QDs during the QD delivery experiment, showing the nanoneedle penetrating through the cell 1043 
membrane. (c-d) Overlay of bright-field and fluorescence image of the cell after the QD 1044 
delivery into c) cytoplasm and d) nuclear. Reproduced with permission.[150] Copyright 2009, 1045 
American Chemical Society. (e) Schematic of the nanotube endoscope. A multiwalled carbon 1046 
nanotube is attached to the end of a glass pipette, which is coated with a non-conducting epoxy 1047 
on the outside and a conducting epoxy on the inside. Inset: Scanning electron micrograph of as-1048 
assembled endoscopes with 100 nm carbon nanotube tips. (f-g) 100 nm nanotube tip of the 1049 
endoscope f) bending and g) elastically recovering its shape when pushed against a cell 1050 
membrane. Reproduced with permission.[151] Copyright 2010, Nature Pulishing Group. 1051 
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 1053 
Figure 7. (a) SEM images of individual mouse embryonic stem (mES) cells penetrated with 1054 
silicon nanowires. The diameter and the length of the nanowires are 90 nm. (b) A confocal 1055 
microscopy image of mES cells penetrated with silicon nanowires. Reproduced with 1056 
permission.[152] Copyright 2008, American Chemical Society. (c-e) Device schematic overview. 1057 
(c) A cross section of a typical device used to deliver biomolecules into cells via nanostraw-1058 
mediated delivery. (d, e) SEM images of critical point dried (CPD) cells cultured on nanostraw 1059 
membranes (false colored green) with 100 nm diameter straws at a density of 108 straws/cm2. 1060 
Reproduced with permission.[154] Copyright 2012, American Chemical Society. (f, g) 1061 
Illustrations of nanostraw-electroporation system. (f) Schematic view of device. (b) Schematic 1062 
illustration of field localization and biomolecule confinement at the tip of the nanostraw due to 1063 
close contact at the nanostraw- plasma membrane interface. Reproduced with permission.[155] 1064 
Copyright 2013, American Chemical Society. 1065 
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 1068 
Figure 8. (a) SEM image of diamond nanoneedles; (b,c) confocal microcopy images of b) 1069 
diamond nanoneedles-treated cells and c) untreated cells c), after 19 hours of incubation with 1070 
luminescent iridium (III) polypyridine complex; (d) and (e) show the normalized emission 1071 
intensity across the lines drawn over the cells in (b) and (c), respectively; The scale bars in (b) 1072 
and (c) are 25 μm. (f) The viability of cells 72 h post plating. The cells were treated with 1073 
diamond nanoneedles, cisplatin or none or both. UT (shown in blue) and T (shown in red) 1074 
indicate that the cells were untreated or treated with nanoneedles, respectively. UT1: the cells 1075 
were treated by neither nanoneedles nor cisplatin; T1: the cells were treated with nanoneedles 1076 
but not cisplatin; UT2: the cells were treated by cisplatin but not nanoneedles; T2: the cells 1077 
were treated by both nanoneedles and cisplatin. Reproduced with permission.[163] Copyright 1078 
2013, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 1079 
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 1080 
Figure 9. (a) Schematic illustration of the unique mechanism governing the nanosubstrate-1081 
mediated delivery (NSMD) approach for both in vivo and in vitro settings. (b) The multivalent 1082 
molecular recognition between the Ad motifs on Ad-SiNWS and the β-cyclodextrin (CD) 1083 
motifs on the surfaces of SNPs leads to dynamic assembly and local enrichment of SNPs onto 1084 
Ad-SiNWS. The Ad/CD recognition system is also responsible for the supramolecular 1085 
assembly of DNA⊂SNPs from the three molecular building blocks (i.e., CD-PEI, Ad-PAMAM, 1086 
and Ad-PEG) and plasmid DNA. Reproduced with permission.[167] Copyright 2014, American 1087 
Chemical Society. 1088 
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